Toshinari Yamashita
Kanagawa, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 87 publications
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: March 30, 2026
Association Between Single-Nucleotide Polymorphism and Trastuzumab Deruxtecan-Induced Interstitial Lung Disease in Breast Cancer Using the Japonica Array NEO.
Journal: Cancers
Published: January 30, 2026
FOXO1 Is Required for Growth and Viability of Cancer-Associated Fibroblasts in Human Breast Carcinomas.
Journal: Genes to cells : devoted to molecular & cellular mechanisms
Published: January 14, 2026
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.
Journal: Breast cancer research and treatment
Published: December 26, 2025
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Journal: The New England journal of medicine
Published: October 29, 2025
Online peer support for breast cancer survivors: protocol for a decentralized multicenter open-label pilot randomized controlled trial (HOPE-BC study).
Journal: International journal of clinical oncology
Published: October 02, 2025
AdipoR1-AMPK axis suppresses breast cancer across molecular subtypes via multimodal cell death pathways, including ferroptosis and apoptosis.
Journal: Cell death & disease
Published: July 30, 2025
Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer.
Journal: NPJ breast cancer
Published: May 22, 2025
A Case of Drug-Induced Pancytopenia due to Tamoxifen.
Journal: Surgical case reports
Published: April 07, 2025
Inflammatory Response during Neoadjuvant Chemotherapy with Immune Checkpoint Inhibitors in a Patient with T3N1 Triple-Negative Breast Cancer: A Case Report.
Journal: Surgical case reports
Published: March 26, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Journal: Nature medicine
Published: March 12, 2025
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 09, 2025
Last Updated: 09/26/2026